Henry Schein (HSIC)
(Delayed Data from NSDQ)
$71.94 USD
-0.96 (-1.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $71.96 +0.02 (0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.94 USD
-0.96 (-1.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $71.96 +0.02 (0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
Zacks News
Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More
by Zacks Equity Research
Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.
Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
Here's Why Henry Schein is Worth Adding to Your Portfolio
by Zacks Equity Research
Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.
Henry Schein Grows on Strategic Buyouts, Competition Rife
by Zacks Equity Research
On Jun 15, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Henry Schein (HSIC) Up 5.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Rides on Global Growth, Strategic Deals
by Zacks Equity Research
On May 25 2017, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Pure Storage (PSTG) Posts Narrower-than-Expected Q1 Loss
by Zacks Equity Research
Pure Storage Inc. (PSTG) reported non-GAAP loss (including stock-based compensation) of 30 cents per share in the first-quarter of fiscal 2018, which was narrower than the Zacks Consensus Estimate by 8 cents.
Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.
Henry Schein (HSIC) Tops Q1 Earnings and Revenues Estimate
by Zacks Equity Research
Headquartered in Melville, NY, Henry Schein Inc. (HSIC) is a global leading provider of healthcare products and services.
Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More
by Zacks Equity Research
Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?
by Zacks Equity Research
Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.
Henry Schein (HSIC) Poised on Solid Growth, Risks Remain
by Zacks Equity Research
On Mar 27, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Henry Schein Inks Agreement for Rijuven's CardioSleeve
by Zacks Equity Research
Henry Schein, Inc. (HSIC) recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. to sell the latter's CardioSleeve device
Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.
Henry Schein (HSIC) Tops Q4 Earnings and Revenues Estimates
by Zacks Equity Research
Henry Schein (HSIC) reported positive fourth quarter 2016 results with earnings and sales exceeding the Zacks Consensus Estimate.
Henry Schein to Acquire SAS to Strengthen Dental Offerings
by Zacks Equity Research
Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).
MedTech Stocks Earnings Slated on Feb 21: MDT, HSIC and More
by Zacks Equity Research
Let's take a look at the major MedTech stocks slated to release their Oct-Dec 2016 numbers on Feb 21.
Henry Schein (HSIC) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Henry Schein, Inc. (HSIC) is expected to report fourth-quarter 2016 financial numbers on Feb 8, before the opening bell.
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
by Zacks Equity Research
On Jan 10, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Henry Schein Named 2016's Best Animal Healthcare Provider
by Zacks Equity Research
Henry Schein, Inc. (HSIC) has been recognized as the "Best Animal Healthcare Product Provider 2016".
Henry Schein Buys Stake in Marrodent; Spurs Polish Foothold
by Zacks Equity Research
Henry Schein (HSIC) has recently completed its earlier announced purchase of 80% ownership of Marrodent.
Henry Schein's Q3 Results Impress, Pricing Pressure a Drag
by Zacks Equity Research
On Dec 6, we issued an updated research report on Melville, NY-based Henry Schein Inc. (HSIC).